SBL
UBX

Sargent Bickham Lagudis’s Unity Biotechnology UBX Stock Holding History

Sargent Bickham Lagudis’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$12K – 1001
2021
Q1 		$12K Hold
200
– – ﹤0.01% 670
2020
Q4 		$10K Hold
200
– – ﹤0.01% 663
2020
Q3 		$7K Hold
200
– – ﹤0.01% 631
2020
Q2 		$17K Hold
200
– – ﹤0.01% 516
2020
Q1 		$12K Hold
200
– – ﹤0.01% 534
2019
Q4 		$14K Buy
+200
New +$14.1K ﹤0.01% 574

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sargent Bickham Lagudis's UBX Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 200 shares — an estimated $12K sold.

Sargent Bickham Lagudis first reported a position in UBX in Q4 2019 and held it in 6 quarters. The position peaked at $17K in Q2 2020. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 200 Unity Biotechnology shares in Q2 2021, an estimated $12K.
  • Sargent Bickham Lagudis first reported a position in Unity Biotechnology in Q4 2019 and held it in 6 quarters.
  • Sargent Bickham Lagudis's Unity Biotechnology position peaked at $17K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.